|
Oct 2
|
Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup
|
|
Oct 1
|
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
|
|
Aug 15
|
Jaguar Health Second Quarter 2024 Earnings: Misses Expectations
|
|
Aug 13
|
Jaguar Health Reports Second Quarter 2024 Financial Results
|
|
Aug 12
|
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
|
|
Jul 31
|
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
|
|
Jul 23
|
Jaguar Health shares slump following Phase III Mytesi failure
|
|
Jul 23
|
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
|
|
Jun 26
|
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
|
|
Jun 21
|
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
|
|
Jun 12
|
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
|
|
Jun 7
|
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 15
|
Jaguar Health Inc (JAGX) Q1 2024 Earnings Call Transcript Highlights: Strategic Expansions and ...
|
|
May 14
|
Jaguar Health Reports First Quarter 2024 Financial Results
|
|
May 13
|
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
|
|
May 9
|
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
|
|
May 8
|
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
|
|
May 7
|
Want $10,000? Invest $1,000 in These 3 Penny Stocks Now
|
|
May 6
|
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
|
|
Apr 29
|
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
|